Title:
P2X3 INHIBITOR COMPOUND, SALT THEREOF, POLYMORPH THEREOF AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/185931
Kind Code:
A1
Abstract:
The present invention relates to a P2X3 inhibitor compound, a salt thereof, a polymorph thereof and use thereof. The present invention provides a crystalline form of a compound of formula I, which has good medicinal properties. A pharmaceutically acceptable salt of the compound of formula I is also obtained, and a crystalline form product of the salt is further obtained, such as a hydrochloride crystalline form A, a maleate crystalline form A, a p-toluenesulfonate crystalline form A, a benzenesulfonate crystalline form A, or a malonate crystalline form A. The present invention has great significance for developing effective therapeutic drugs.
Inventors:
ZHANG XUEJUN (CN)
ZANG YANG (CN)
LI QUN (CN)
LEI SIJUN (CN)
LIU LIFEI (CN)
LI YUAN (CN)
XIA QINGFENG (CN)
LI LI'E (CN)
YANG JUN (CN)
ZANG YANG (CN)
LI QUN (CN)
LEI SIJUN (CN)
LIU LIFEI (CN)
LI YUAN (CN)
XIA QINGFENG (CN)
LI LI'E (CN)
YANG JUN (CN)
Application Number:
PCT/CN2023/084726
Publication Date:
October 05, 2023
Filing Date:
March 29, 2023
Export Citation:
Assignee:
HUMANWELL HEALTHCARE GROUP CO LTD (CN)
WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY (CN)
WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY (CN)
International Classes:
C07D417/12; A61K31/427; A61K31/506; A61P13/00; A61P25/04; A61P29/00
Domestic Patent References:
| WO2022068930A1 | 2022-04-07 | |||
| WO2019219672A1 | 2019-11-21 | |||
| WO2020260463A1 | 2020-12-30 | |||
| WO2021245512A1 | 2021-12-09 |
Foreign References:
| CN107207507A | 2017-09-26 |
Attorney, Agent or Firm:
BEIJING ORIGINTELLIGENCE IP LAW FIRM (CN)
Download PDF: